Sanofi's Dengvaxia: ACIP Decision On Use Will Hinge On Screening Test
CDC advisory committee cannot recommend administration of Sanofi's dengue vaccine until there is an acceptable test to detect previous dengue infection and other questions are answered.
You may also be interested in...
Sanofi spends 70% of vaccine production on quality control, Sanofi Pasteur exec VP David Loew tells the Pink Sheet; company is working on next generation flu vaccines that may provide greater efficacy.
Dengvaxia’s Restrictive Indication Will Make Immunization Recommendations Difficult, ACIP Members Say
The need to screen individuals in dengue-endemic areas for prior infection before administering Sanofi’s vaccine will be difficult to operationalize, particularly in the absence of a reliable and rapid diagnostic, experts say; Advisory Committee on Immunization Practices working group aims for full committee vote on use recommendations in February 2020.
Keeping Track: US FDA Approves Sanofi’s Dengvaxia, But Heron’s HTX-011 And Nabriva’s Contepo Fall Short
The latest drug development news and highlights from our US FDA Performance Tracker.